Comparative Pharmacology
Head-to-head clinical analysis: CLARINEX D 12 HOUR versus FAYOSIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARINEX D 12 HOUR versus FAYOSIM.
CLARINEX-D 12 HOUR vs FAYOSIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.
FAYOSIM (plecanatide) is a guanylate cyclase-C (GC-C) agonist. It binds to GC-C receptors on the luminal surface of intestinal epithelial cells, activating the receptor and increasing intracellular cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP stimulates chloride and bicarbonate secretion into the intestinal lumen, enhancing fluid secretion and accelerating gastrointestinal transit, thereby promoting bowel movements.
1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.
10 mg orally once daily
None Documented
None Documented
Desloratadine: 27 hours (terminal), allows once-daily dosing; pseudoephedrine: 4-6 hours (prolonged in alkaline urine).
12-16 hours in healthy adults; prolonged to 20-30 hours in moderate renal impairment (CrCl <50 mL/min) requiring dose adjustment.
Desloratadine: 40.2% renal (unchanged and metabolites), 41.7% fecal; pseudoephedrine: 70-90% renal (unchanged).
Primarily renal elimination, 80% unchanged drug in urine; 15% biliary/fecal; 5% metabolized.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine